For patients with neuroendocrine tumors that have spread to other areas of the body or are recurrent despite other therapy, or are not operable, Lutathera presents a novel option to deliver precise therapy. Lutathera is a special radionucleotide of lutetium-177 dotatate or a radiolabeled somatostatin analogy. Once delivered into the veins, Lutathera travels throughout the body searching for neuroendocrine cancer cells. Once it finds these tumor cells, radiation is released to treat these cancer cells throughout the body.

In a large clinical trial, patients who received Lutathera lived longer than those who did not. Because this treatment is specifically targeted to neuroendocrine cancer cells throughout your body, the risk of serious adverse effects are low compared to more traditional drug options.